WANY
AMRX icon

Wealthspire Advisors (New York)’s Amneal Pharmaceuticals AMRX Stock Holding History

Wealthspire Advisors (New York)’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-24
Closed -$240 – 1114
2025
Q3 		$240 Buy
+24
New +$215 ﹤0.01% 2921

Other funds holding AMRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Wealthspire Advisors (New York)'s AMRX Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of Amneal Pharmaceuticals (AMRX) in Q4 2025, closing a stake of 24 shares — an estimated $240 sold.

Wealthspire Advisors (New York) first reported a position in AMRX in Q3 2025 and held it in 1 quarter. The position peaked at $240 in Q3 2025. 277 funds tracked by Wall St. Rank hold AMRX as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining Amneal Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 24 Amneal Pharmaceuticals shares in Q4 2025, an estimated $240.
  • Wealthspire Advisors (New York) first reported a position in Amneal Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s Amneal Pharmaceuticals position peaked at $240 in Q3 2025.
  • 277 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.